Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2

Philadelphia, PA, August 22-26, 2004 - ACS Division of Medicinal

Malcolm MacCoss's research works Merck & Co., Whitehouse Station (MSD) and other places

Full article: Chemokine receptor antagonists: Part 1

Full article: Future therapeutic treatment of COPD: Struggle between oxidants and cytokines

Full article: Chemokine receptor antagonists: Part 1

CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. - Abstract - Europe PMC

US7834021B2 - 3-aminopyrrolidine derivatives as modulators of chemokine receptors - Google Patents

Roles of Chloride and Sulfate Ions in Controlling Cadmium Transport in a Soil-Rice System as Evidenced by the Cd Isotope Fingerprint

MEDI 1 - ACS Division of Medicinal Chemistry Homepage

Small molecules in the treatment of COVID-19

A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894) Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6+ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation